Story perspectives

Boston Scientific Cuts Outlook After Cyberattack, Warns Slower Growth

By Drooid · Oct 29, 2026 · How we work

Read the story

Story summary

Summary

Boston Scientific cut its full-year earnings outlook to $3.16-$3.18 per share.
Its shares fell 9% in New York, extending a 53% year-to-date loss.
An August cyberattack disrupted operations, shaving 300 basis points of sales growth and $0.07 EPS.
CFO Jon Monson warned China pricing pressure and heart-device weakness will curb 2027 growth.
Jefferies and JPMorgan downgraded the stock, cutting price targets to $46 from $60 and $56.

1 of 1

Boston Scientific cut its full-year earnings outlook to $3.16-$3.18 per share.
Its shares fell 9% in New York, extending a 53% year-to-date loss.
An August cyberattack disrupted operations, shaving 300 basis points of sales growth and $0.07 EPS.
CFO Jon Monson warned China pricing pressure and heart-device weakness will curb 2027 growth.
Jefferies and JPMorgan downgraded the stock, cutting price targets to $46 from $60 and $56.